When Does NICE Recommend the Use of Health Technologies Within a Programme of Evidence Development? A Systematic Review of NICE Guidance

TY - JOUR

T1 - When Does NICE Recommend the Use of Health Technologies Within a Programme of Evidence Development?

T2 - A Systematic Review of NICE Guidance

AU - Longworth, Louise

AU - Youn, Jihee

AU - Bojke, Laura

AU - Palmer, Stephen

AU - Griffin, Susan

AU - Spackman, Eldon

AU - Claxton, Karl

PY - 2013/2

Y1 - 2013/2

N2 - There is growing interest internationally in linking reimbursement decisions with recommendations for further research. In the UK, the National Institute for Health and Clinical Excellence (NICE) can issue guidance to approve the routine use of a health intervention, reject routine use or recommend use within a research programme. These latter recommendations have restricted use to 'only in research' (OIR) or have recommended further research alongside routine use ('approval with research' or AWR). However, it is not currently clear when such recommendations are likely to be made.

AB - There is growing interest internationally in linking reimbursement decisions with recommendations for further research. In the UK, the National Institute for Health and Clinical Excellence (NICE) can issue guidance to approve the routine use of a health intervention, reject routine use or recommend use within a research programme. These latter recommendations have restricted use to 'only in research' (OIR) or have recommended further research alongside routine use ('approval with research' or AWR). However, it is not currently clear when such recommendations are likely to be made.

UR - http://www.scopus.com/inward/record.url?scp=84876266455&partnerID=8YFLogxK

U2 - 10.1007/s40273-012-0013-6

DO - 10.1007/s40273-012-0013-6

M3 - Article

C2 - 23329429

SN - 1170-7690

VL - 31

SP - 137

EP - 149

JO - Pharmacoeconomics

JF - Pharmacoeconomics

IS - 2

ER -